A previous study demonstrated that intracranial tumor volume had some correlation with gastrointestinal cancer patients' outcome. The aim of this study was to analyze patients with esophageal carcinoma (EC) and brain metastases to investigate if intracranial tumor volume would be a predictor of these patients' survival. Methods: A total of 52 patients with brain metastases from esophageal squamous cell carcinoma or esophageal adenocarcinoma were retrospectively reviewed. Patients without images of brain metastases in the hospital information system were eliminated.Results: The median follow-up time duration was 8.4 months (interquartile range 4.0-15.2). The median overall survival (OS) from time of brain metastases diagnosis was 8.0 months for all cases. Median OS of patients with small and large cumulative intracranial tumor volume (CITV) (<6.65 cm 3 , ≥6.65 cm 3 ) was 11.23 and 7.4 months, respectively. Median OS of patients with large and small largest intracranial tumor volume (LITV) (≥7.75 cm 3 , <7.75 cm 3 ) was 6.4 and 10.6 months, respectively. Univariate analysis demonstrated that CITV (hazard ratio [HR] 1.255, 95% confidence interval [CI] 0.673-2.342, p = 0.475) or LITV (HR 1.037, 95% CI 0.570-1.887, p = 0.904) was not significantly associated with improved OS. Multivariate analysis demonstrated that CITV and LITV were not significantly associated with improved OS. Conclusion: EC patients with small intracranial tumor volume may have longer OS than those with large intracranial tumor volume, but this difference did not reach statistical difference. Future studies with a larger sample size may validate the correlation of intracranial tumor volume and patient survival.

Background: The standard treatment for advanced unresectable non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy. However, many poor Karnofsky score or elderly patients cannot tolerate it due to heir serious side effects. For patients who cannot tolerate concurrent chemoradiotherapy, conventional treatment is sequential chemoradiotherapy or radiotherapy alone. But the median survival time of sequential chemoradiotherapy and radiotherapy alone is 11-16 months. In order to improve curative effect, radiotherapy, as an important treatment method, has been tried, innovated and improved continuously. The goal of this trial is to evaluate feasibility and safety of isotoxic hypofractionated radiotherapy in patients with NSCLC. Methods: This is a phase Ⅱ open-label multi-center two-step non-randomised Trial. In the first stage, 12 patients will be included in the trial with radiotherapy of 3Gy per fraction. If more than 3 patients have serious side effects of radiotherapy, the trial will be terminated. Otherwise, the second phase will continue, and the total number of participants will be 30. All patients eventually will be followed up for 5 years. The primary endpoint is the safety of isotoxic hypofractionated radiotherapy. The secondary outcomes are time to progression (TTP), progression free survival (PFS), overall survival (OS), local control (LC). Discussion: In clinical practice, the local control rate of conventional fractionated radiotherapy for NSCLC is very low. We hope that this trial can verify the safety of isotoxic hypofractionated radiotherapy. Trial Registration: NCT03606291, REGISTERED JULY, 30, 2018.